NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Delcath Systems, Inc. DCTH
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$85.2M
▲ 129.1% vs FY2024
EPS · FY25
$0.07
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
3.0%
Net margin · FY25
3.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 85.2M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
3 cents of every revenue dollar became profit this year.
Per share
USD 0.07
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
3.0%
Return on equity, FY2025
ROE
Operating margin0.8%
Net margin3.2%
Return on assets2.7%
Each USD of equity produced 3 cents of profit this year.
Returned to shareholders
USD 5.5M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 5.5M
Share of profit204.4%
Consecutive raises—
USD 5.5M in buybacks — 204% of the year's profit, so the payout drew on cash built up earlier.
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+215.3%
+47.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 123.6M
total assets, end of FY2025
Total assetsUSD 123.6M
EquityUSD 111.2M
CashUSD 43.5M
Current ratio10.92×
Equity funds 90% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.0
0.0
0.0
0.0
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Net income $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
0.07
−0.93
−2.94
−4.12
−3.59
−8.35
−342.83
−504.00
−3250.00
−3707.00
−5096.00
−1.84
−5.10
−13.54
−0.68
−1.20
−0.82
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
3.0
−62.4
−961.4
−1198.4
−150.7
−307.3
·
·
·
−505.4
−110.0
−72.1
−121.0
−225.0
−111.9
−176.7
−129.9
Shares out B
0.03
0.03
0.02
0.01
0.01
0.01
0.00
0.00
0.00
0.00
0.00
0.01
0.01
0.08
0.05
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
61 of 61
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed